Boiler Room: The Official Stock Market Discussion

[Bernie Madoff]

Breh I gave up the coli but had to come back just to you.

FDA lifted the hold on that drug...ACHN shares up some ridiculous amount pre-market after yesterdays meteoric rise.

I had taken the last few weeks to average my cost down to 2.98 per share.

We are about to fukkING FEAST today.

If this shyt gets bought out... .

Aye, we made it!

 

[BlvdBrawler]

Aye, we made it!

Which begs the question.... Do I take 119% and run, or do I hold and hope for a buyout?

 

[GoogleMe]

@Bernie Madoff

your favorite stock ACHN up 40%...on no news other than some other Hep C company got bought out?

Up around 80% from my first purchase

And you know I had some calls in the glove box. Shout out to ra capital!
Qvt

 

[Bernie Madoff]

Which begs the question.... Do I take 119% and run, or do I hold and hope for a buyout?

Beauty about this jump imo, is this is actually the correct valuation so it's not going to plummet back down anytime soon which really lowers the risk.


With the cash and portfolio ACHN has they really don't need a buy out at the moment....

 

[DEAD7]

mpicpp (3454017) writes with news that GoDaddy has filed to make an initial public offering"This is the second time GoDaddy has tried to go public. It went this route back in 2006, but then backed out when it didn't get the pricing it wanted."The SEC Filing indicates that they are not in the greatest financial condition. Quoting CNN: "GoDaddy hasn't made a profit since 2009. The company lost $279 million in 2012. It bled another $200 million last year. This year doesn't look much better, with another $51 million lost in the first quarter." Founder Bob Parsons, currently executive chairman, will be stepping down but remaining on the board of directors.

 

[Ohene]

mpicpp (3454017) writes with news that GoDaddy has filed to make an initial public offering"This is the second time GoDaddy has tried to go public. It went this route back in 2006, but then backed out when it didn't get the pricing it wanted."The SEC Filing indicates that they are not in the greatest financial condition. Quoting CNN: "GoDaddy hasn't made a profit since 2009. The company lost $279 million in 2012. It bled another $200 million last year. This year doesn't look much better, with another $51 million lost in the first quarter." Founder Bob Parsons, currently executive chairman, will be stepping down but remaining on the board of directors.

say word. Ill be watching that IPO very very closely. seems like a desperation move on their part.

I got my eye on VRX right now...Thinking of puts for the short term. It's at a pivotal place right now with 125, , 121, 115 and 108 being key prices

 

[Bernie Madoff]

Catalyst will be one of 3 things
1.hold removed
2.the ac3102 enters phase 3
3.buy out

+20 % of the stock is short, and when this pops its going to pop.

Floor was hit at 2.40. Just look at the charts on the stock and how it trades. Bullish closes everyday!

Once it breaks 2.90 the next stop is 3.60's.

2.92 covering begins
http://www.schaeffersresearch.com/marketcenters/optionscenter/content/option bears hit achillion pharmaceuticals inc achn on news/default.aspx?ID=117963

ACHN has been the subject of a number of recent research reports. Analysts at Credit Suisse downgraded shares of Achillion Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday. Separately, analysts at Deutsche Bank downgraded shares of Achillion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note to investors on Monday, September 30th. Finally, analysts at Wells Fargo & Co. downgraded shares of Achillion Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note to investors on Monday, September 30th. One investment analyst has rated the stock with a sell rating and eleven have assigned a hold rating to the company’s stock. Achillion Pharmaceuticals has an average rating of “Hold” and an average target price of $6.07.

It didnt get rejected per say the FDA just didnt lift a hold on sep 27 that had originally been placed in June.

The FDA's response indicated that while Achillion's submission addressed all the issues noted in the FDA's June 29 letter, the FDA concluded that the removal of the clinical hold is not warranted, said the company.

"While we are disappointed that we were not able to resolve the clinical hold at this time despite having addressed all the issues, we believe the breadth of our portfolio allows us to quickly advance other all oral combination regimens for the treament of [hepatitis C virus]," said Chief Executive Milind Deshpande.

In July, Achillion had said the FDA put the drug on clinical hold after the company's early-stage study of drug interactions in healthy patients resulted in elevated liver enzymes tied to higher-than-expected exposures to sovaprevir and another drug, atazanavir.

The company had voluntarily stopped dosing in the study after finding high levels of the liver enzymes in several people enrolled in the study. Its preliminary investigation found that dosing with both of the drugs caused a metabolic interaction that substantially increased the plasma concentration of both drugs.

No serious adverse events were reported at that time.

The FDA has continued to allow the enrollment of patients in a separate midstage study evaluating sovaprevir in combination with other drugs in patients with hepatitis C.

:yea:

On Friday, Achillion announced interim data from its ongoing Phase 2a clinical trial of two doses of sovaprevir in combination with ACH-3102 and ribavirin, saying to date the combination has been well tolerated with no drug-related serious adverse events, no clinically significant changes in vital signs or electrocardiograms, no graded increases in liver unciton tests, and no other laboratory abnormalities were noted with the exception of decreases in hemoglobin observed and attributed to ribavirin.

Achillion is competing with Bristol-Myers Squibb Co. (BMY) and Gilead Sciences Inc. (GILD) to bring an all-oral hepatitis C regimen to market, hoping to capitalize on what is expected to be a multibillion-dollar market for the therapy.

 

[GoogleMe]

say word. Ill be watching that IPO very very closely. seems like a desperation move on their part.

I got my eye on VRX right now...Thinking of puts for the short term. It's at a pivotal place right now with 125, , 121, 115 and 108 being key prices

Godaddy's s-1 http://www.sec.gov/Archives/edgar/data/1609711/000119312514230425/d728713ds1.htm#toc728713_3

 

[GoogleMe]

@Domingo Halliburton thanks for mentioning achn when you did

 

[Domingo Halliburton]

@Domingo Halliburton thanks for mentioning achn when you did

no problem. you get in on the spike today?

 

[GoogleMe]

no problem. you get in on the spike today?

I got in small yesterday > 4, then some more in the pre-market today. Biotechs tend to move off of a competitors positive/negative news

 

[GoogleMe]

http://www.bloomberg.com/news/2014-...across-europe-as-taxi-app-backlash-grows.html

 

[Ohene]

CBS

 

[ill]

Not only did I sell achn a day early but I bought a few $4calls that day and sold then an hour later cuz I saw the pps fading. 400 in calls would've netted like 3k. Terrible time for me to need cash and be risk averse.

 

[Ohene]

http://www.bloomberg.com/news/2014-06-11/cbs-to-fully-divest-81-stake-in-cbs-outdoor-americas.html

CBS Corp. (CBS) took the final step in the spinoff of its billboard business following CBS Outdoor Americas Inc. (CBSO)’s initial public offering, with a plan to fully divest its 81 percent ownership.

The exchange offer is expected to be tax free for shareholders in the U.S., New York-based CBS, owner of the most-watched television network, said today in a statement.

After the split, CBS Outdoor intends to convert into a real estate investment trust, or REIT. In March, the company raised $560 million in an IPO and said the proceeds would help complete the conversion. At the time, CBS Outdoor Chief Executive Officer Jeremy Male said the company would seek to buy smaller U.S. billboard companies.

By splitting off from CBS and becoming a REIT, the business will have the ability to buy competitors in the 25 biggest U.S. markets and convert more locations to more-profitable electronic signs, Male said in March.

REITs have become a popular tool for companies to lower taxes and improve returns for investors. REITs don’t pay federal income taxes and are required to distribute at least 90 percent of taxable earnings as dividends.

CBS Outdoor will compete with Lamar Advertising Co. and Clear Channel Outdoor Holdings Inc. and put a priority on digital billboards.